Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II hodgkin disease: A prospective multicenter study

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 3, 2011, Pages 823-828

  Pommier, Pascal ^a   Dussart, Sophie ^a   Girinsky, Théodore ^b   Chabaud, Sylvie ^a   Lagrange, Jean Leon ^c   Nguyen, Tan Dat ^d   Beckendorff, Véronique ^e   Dhombres, Anne ^f   Artignan, Xavier ^g   Bondiau, Pierre Yves ^h   Carrie, Christian ^a   Giammarile, Francesco ^a,f  

^a UNIVERSITÉ DE LYON   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d INSTITUT JEAN GODINOT   (France)

^e CENTRE ALEXIS VAUTRIN   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Hodgkin disease; Positron emission tomography; Prospective study; Radiotherapy

Indexed keywords

COMPUTED TOMOGRAPHY; EMISSION TOMOGRAPHY; FDG-PET; HODGKIN DISEASE; MULTICENTER STUDY; PLAN-BASED; POSITRON EMISSION; PROSPECTIVE STUDY; RADIOTHERAPY PLANNING; TOTAL DOSE; TREATMENT PLANNING; TREATMENT PLANS;

CHEMOTHERAPY; COMPUTERIZED TOMOGRAPHY; DISEASES; ELECTRONS; POSITRONS; RADIOTHERAPY;

POSITRON EMISSION TOMOGRAPHY;

FLUORODEOXYGLUCOSE F 18; IODINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL STAFF; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN; YOUNG ADULT;

EID: 79551474511     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.11.048     Document Type: Article

References (19)

1. A. Gallamini, M. Hutchings, and L. Rigacci Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkins lymphoma: A report from a joint Italian-Danish study J Clin Oncol 25 2007 3746 3752
2. C. Guay, M. Lepine, and J. Verreault Prognostic value of PET using 18F-FDG in Hodgkins disease for posttreatment evaluation J Nucl Med 44 2003 1225 1231
3. M. Hutchings, A. Loft, and M. Hansen FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma Blood 107 2006 52 59
4. L. Kostakoglu, M. Coleman, and J.P. Leonard PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkins disease J Nucl Med 43 2002 1018 1027
5. K. Spaepen, S. Stroobants, and P. Dupont Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkins lymphoma Ann Oncol 13 2002 1356 1363
6. T. Torizuka, F. Nakamura, and T. Kanno Early therapy monitoring with FDG-PET in aggressive non-Hodgkins lymphoma and Hodgkins lymphoma Eur J Nucl Med Mol Imaging 31 2004 22 28
7. M. de Wit, K.H. Bohuslavizki, and R. Buchert 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkins lymphoma Ann Oncol 12 2001 29 37
8. G. Jerusalem, Y. Beguin, and M.F. Fassotte Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkins disease and non-Hodgkins lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging Blood 94 1999 429 433
9. K. Spaepen, S. Stroobants, and P. Dupont Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkins lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19 2001 414 419
10. P.L. Zinzani, M. Magagnoli, and F. Chierichetti The role of positron emission tomography (PET) in the management of lymphoma patients Ann Oncol 10 1999 1181 1184
11. B.D. Cheson, B. Pfistner, and M.E. Juweid Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586
12. T. Girinsky, M.R. van der, and L. Specht Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines Radiother Oncol 79 2006 270 277
13. L. Specht 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas Semin Radiat Oncol 17 2007 190 197
14. M.E. Juweid, S. Stroobants, and O.S. Hoekstra Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol 25 2007 571 578
15. H. Vorwerk, S. Obenauer, and H. Schmidberger The significance of a uniform definition of pathological lymph nodes in Hodgkin lymphoma: Impact of different thresholds for positive lymph nodes in CT imaging on staging and therapy Radiother Oncol 87 2008 74 81
16. M. Picardi, A. De Renzo, and F. Pane Randomized comparison of consolidation radiation versus observation in bulky Hodgkins lymphoma with post-chemotherapy negative positron emission tomography scans Leuk Lymphoma 48 2007 1721 1727
17. T. Girinsky, M. Ghalibafian, and G. Bonniaud Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiother Oncol 85 2007 178 186
18. M. Hutchings, A. Loft, and M. Hansen Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma Eur J Haematol 78 2007 206 212
19. Y.K. Lee, G. Cook, and M.A. Flower Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma Radiother Oncol 73 2004 277 283